Skip to main content
. 2014 Nov 20;78(6):1315–1333. doi: 10.1111/bcp.12418

Figure 1.

Figure 1

Study design and dose escalation schedule. Blue arrows represent dosing; black arrows represent pharmacokinetic, pharmacodynamic, immunogenicity, safety and/or effect assessment visits. Numbers in parenthesis indicate AMG 181: placebo randomization ratio per study protocol and the number of subjects (N) completing the study. s.c. = subcutaneous; i.v. = intravenous; UC = ulcerative colitis subjects else, healthy subjects